1. Scrip
  2. >>Business
  3. >>Deals

CytomX’s Probody T-Cell Platform Produces Astellas Pact

Bispecifics collaboration with Astellas May Be Worth $1.6bn For CytomX

 
• By Sten Stovall

Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.  

Antibodies_Cancer
Probody T-cells bind selectively to tumors, minimizing healthy tissue damage • Source: Shutterstock

CytomX Therapeutics Inc. has landed its second strategic bispecifics collaboration, this time with Astellas Pharma Inc. of Japan in a deal potentially worth more than $1.6bn that focuses on the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens, for the treatment of cancer.

Under the deal, announced on 23 March, CytomX is eligible for high-single to mid-teen royalties, and may also exercise an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial